CD33 and acute myeloid leukemia: The following AML-specific targets have been identified as promising and are currently under investigation (Table 2): CD33 [83], CD123 [84], CLL-1 [85], NKG2D ligand [86], CD43 [87], CD96 [88], interleukin-3 receptor alpha chain [89], TIM-3 [90], CD38 [91], CD157 [92], CD44v6 [93], and CD47 [94], among others [95].